{"id":963514,"date":"2026-05-15T10:20:16","date_gmt":"2026-05-15T14:20:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmatrix-announces-first-quarter-2026-financial-results\/"},"modified":"2026-05-15T10:20:16","modified_gmt":"2026-05-15T14:20:16","slug":"pulmatrix-announces-first-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmatrix-announces-first-quarter-2026-financial-results\/","title":{"rendered":"Pulmatrix Announces First Quarter 2026 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Announced merger agreement with Eos SENOLYTIX in March<\/i>\n <\/p>\n

\n Closed private placement of preferred stock<\/i>\n <\/p>\n

\n FRAMINGHAM, Mass.<\/span>, May 15, 2026<\/span> \/PRNewswire\/ — Pulmatrix, Inc.<\/a> (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE\u2122 technology, today announced its first quarter financial results for 2026 and provided a corporate update.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Pulmatrix,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, “Our focus in the first quarter was on our work to secure a strategic transaction for our company and our shareholders. We are pleased to report that on March 26th<\/sup>\u00a0we announced entering into a merger agreement with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using its proprietary MitoXcel\u2122 platform. We also secured aggregate gross proceeds of $1 million from a private placement of preferred stock from an affiliate of Eos. Separate from the preferred stock, our common stockholders will receive approximately 6% interest in the new combined company without dilution from the preferred stock.”<\/p>\n

\n
\n Proposed Merger with Eos SENOLYTIX<\/i>
\n <\/b>\n <\/p>\n

As previously reported, on March 26, 2026, the Company entered into an agreement (the “Merger Agreement”) and plan of merger (the “Merger”) with Eos SENOLYTIX, Inc. (“Eos”). The proposed Merger is anticipated to close in the third quarter of 2026, subject to customary closing conditions. If the proposed Merger is completed, the business of Eos will continue as the business of the combined company.<\/p>\n

In connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred Stock, raising aggregate gross proceeds of $1.0 million.<\/p>\n

Additional information about the Merger Agreement was previously disclosed on a Current Report on Form 8-K filed with the SEC on March 27, 2026.<\/p>\n

\n Pulmatrix Seeks to Out-license or Monetize its Clinical Assets<\/b>\n <\/p>\n

\n
\n iSPERSE\u2122 Technology<\/i>
\n <\/b>\n <\/p>\n